WYOMING MEDICAID
Preferred Drug List (PDL) - January 1, 2016

Drug classes not included on this list are not managed through a Preferred Drug List (PDL).
HOWEVER, THIS EXCLUSION IS NOT A GUARANTEE OF PAYMENT OR COVERAGE. Dosage limits and other requirements may apply.

Drugs new to market are non-preferred until a clinical review has been completed. PA criteria will apply to both the pediatric population, as well as the adult population for those plans where PA/PDL limits are allowed.

Unless otherwise noted on the PDL, generic substitution is mandatory.

Yellow highlighted items below indicate new changes to the PDL. Red font indicates quantity/dosage limits apply. *Indicates BRAND is Preferred. May Use DAW 5.
Contact the GHS PA Helpdesk @ 877-207-1126 for prior authorization if client has primary insurance that will not cover the brand name medication.

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT GHS FOR QUESTIONS
ADDICTION AGENTS	**BUPRENORPHINE COMBINATIONS**	SUBOXONE FILM	Client must have a diagnosis of opioid dependence or abuse. This is not to be used for the treatment of chronic pain. Prescriber must have a XDEA number. Prior authorization will be required before any narcotic or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any benzodiazepine or short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills. Oral buprenorphine will be approved for clients that are pregnant or nursing or with a documented allergy to naloxone. Dosage limits apply (Max Dose: 24mg/day). Client is limited to two (2) years of buprenorphine/naloxone or oral buprenorphine use. Please submit PA requests on the "Oral Buprenorphine/Naloxone or Oral Buprenorphine" PA form available at www.wymedicaid.org.	BUNAVAIL buprenorphine (oral) buprenorphine/naloxone tablets (use preferred) ZUBSOLV
	NALTREXONE	naltrexone VIVITROL	Client must have a diagnosis of alcohol or opioid dependance. Prior authorization will be required before any narcotic or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any benzodiazepine or short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills.	
ALLERGY / ASTHMA	**ANTIHISTAMINES, MINIMALLY SEDATING**	cetirizine fexofenadine loratadine	Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	desloratadine CLARINEX RDT/SYRUP levocetirizine
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS	cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine	Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CLARINEX-D
	ANTICHOLINERGIC BRONCHODILATORS	COMBIVENT ipratropium SPIRIVA HANDIHALER	Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Spiriva 5 day STARTER package will be allowed one (1) time per recipient.	ATROVENT HFA INCRUSE ELLIPTA SPIRIVA RESPIMAT TUDORZA
	CORTICOSTEROID / BRONCHODILATOR COMBO'S	ADVAIR DISK/HFA DULERA SYMBICORT	Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. ***Will also require the diagnosis of COPD. Advair 7 and 14-day STARTER package will be allowed one (1) time per recipient.	ANORO ELLIPTA*** BREO ELLIPTA*** STIOLTO
	LEUKOTRIENE MODIFIERS	montelukast	Trial and failure of preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	zafirlukast ZYFLO
	LONG ACTING BRONCHODILATORS	BROVANA SEREVENT	Trial and failure of two (2) preferred agents greater than or equal to 30 days int the last 12 months will be required before approval can be given for a non-preferred agent.	PERFOROMIST STRIVERDI
	NASAL ANTIHISTAMINES	**ASTELIN** azelastine 0.1%	Trial and failure of preferred agent greater than or equal to 90 days in the last 12 months will be required before approval can be given for a non-preferred agent.	azelastine 0.15% AZENASE *(use separate agents)* DYMISTA *(use separate agents)* olopatadine 0.6%
	NASAL STEROIDS	BECONASE AQ flunisolide fluticasone NASONEX	Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Budesonide will be approved for pregnancy.	AZENASE *(use separate agents)* budesonide DYMISTA *(use separate agents)* OMNARIS QNASL triamcinolone VERAMYST ZETONNA
	SHORT ACTING BRONCHODILATORS - INHALERS	PROAIR HFA PROVENTIL HFA VENTOLIN HFA	Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Minimum day supply of at 16 days is required	PROAIR RESPICLICK XOPENEX HFA
	SHORT ACTING BRONCHODILATORS - NEBULIZERS	albuterol neb **XOPENEX neb***	Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	levalbuterol (BRAND IS PREFERRED)

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT DHS FOR QUESTIONS)
ALLERGY / ASTHMA continued	**STEROID INHALANTS**		Trial and failure of three (3) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Alvesco will be approved for a history of oral thrush with steroid inhalants.	AEROBID/AEROBID-M ALVESCO ARNUITY ASMANEX budesonide susp 0.25mg/2ml AND 0.5mg/2ml (BRAND IS PREFERRED) budesonide susp 1mg/2ml QVAR
	AEROSPAN FLOVENT HFA/DISK **PULMICORT SUSP 0.25mg/2ml AND 0.5mg/2ml*** PULMICORT FLEXHALER			
	EPINEPHRINE			ADRENACLICK *(use preferred)* AUVI-Q *(use preferred)* epinephrine *(use preferred)*
	EPI-PEN			
ALZHEIMERS	**ALZHEIMER AGENTS**		Client must have a diagnosis of dementia.	donepezil 23mg *(use preferred)* donepezil ODT *(use preferred)* rivastigmine patches (BRAND IS PREFERRED)
		donepezil **EXELON PATCH*** galantamine/ER memantine tablets/solution NAMENDA XR rivastigmine capsules		
ANALGESICS	**LONG-ACTING C-IIs**		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. C-IIIs and C-IVs that are not included on the PDL and are available without prior authorization with the exception of Butrans (generic substitution is mandatory). Fentanyl patches will require a prior authorization unless a client has a cancer diagnosis or previous treatment of at least a 10 day supply within the last 45 days **Butrans requires a trial of morphine sulfate ER or low dose trial of fentanyl patch. ***Nucynta ER will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics. ****In addition to above criteria, Embeda requires a diagnosis of drug/substance abuse. Fentanyl patches are limited to one patch every 72 hours. Butrans: 20mcg, 1 strength at a time, 1 patch every 7 days Fentanyl: 75mcg, 1 strength at a time, 1 patch every 3 days Hysingla ER: 180mg/day Hydromorphone ER: 32mg/day Morphine ER: 180mg/day Methadone: Limited to 3 tablets per day Nucynta ER: 490.5mg/day Oxycontin: 120mg/day Oxymorphone ER: 60mg/day Xartemis XR: 120mg/day Zohydro ER: 180mg/day Clients will be limited to one long-acting narcotic at a time	AVINZA BUTRANS** EMBEDA**** fentanyl patch 37.5, 62.5, 87.5mg *(use preferred)* hydromorphone ER HYSINGLA ER *(additional criteria applies)* KADIAN 200mg *(use preferred)* METHADONE morphine sulfate ER capsules *(use preferred)* NUCYNTA ER*** oxymorphone ER **OXYCONTIN*** XARTEMIS XR *(additional criteria applies)* ZOHYDRO ER *(additional criteria applies)*
	morphine sulfate ER tablets	fentanyl patch 12.5, 25, 50, 75, and 100mg		
	SHORT-ACTING C-IIs		Trial and failure of three (3) preferred agents greater than or equal to a 6 day supply in the last 90 days will be required before approval can be given for a non-preferred agent. **In addition to above criteria, Oxecta require a diagnosis of drug/substance abuse. ***Nucynta will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics. All short-acting narcotics, after 42 days of consecutive use of any combination of short-acting narcotics, will be limited to 6 tablets per day (liquids have specific dosing limits per medication - please refer to dosage limitation chart at www.wymedicaid.org) Clients will be limited to one short-acting narcotic at a time	levorphanol NUCYNTA*** OXAYDO** OXECTA** oxymorphone oxycodone/IBU PRIMLEV *(use preferred)* ZOLVIT SOLUTION *(use preferred)*
	codeine sulfate hydrocodone/APAP hydrocodone/IBU hydromorphone LORTAB ELIXIR 10-300MG morphine sulfate oxycodone oxycodone/APAP oxycodone/ASA			
	C-III/C-V AGENTS		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Quantity and dosage limits apply (max 8 tabs/day). **Butrans will require a 14 day trial and failure of tramadol IR and a 14 day trial and failure of tramadol ER prior to approval	BUTRANS** CONZIP RYBIX ODT tramadol/apap tramadol ER
	tramadol			
ANDROGENS	**TESTOSTERONE TOPICAL GELS**		Testosterone agents are only allowed for diagnosis of hypogonadism or insufficient testosterone production. *Other testosterone dosage form products will require a diagnosis of hypogonadism or insufficient testosterone production (not outlined on PDL).*	NATESTO NASAL GEL *(use preferred)* TESTIM GEL *(use preferred)* testosterone gel 1% (BRAND IS PREFERRED) testosterone gel 2% *(use preferred)* VOGELXO GEL (use preferred)
		ANDROGEL*		

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
ANTIBIOTICS	**QUINOLONES**			FACTIVE moxifloxacin NOROXIN PROQUIN
	ciprofloxacin/ER levofloxacin ofloxacin			
	DOXYCYCLINE			ADOXA *(use preferred)* DORYX *(use preferred)* ORACEA *(use preferred)*
	doxycycline			
	MINOCYCLINE			SOLODYN *(use preferred)*
	minocycline/ER			
	INHALED TOBRAMYCIN		*Tobi Podhaler requires a 28 day trial of Kitabis, as well as 28 days off of Kitabis prior to approval. Minimum day supply of at 56 days is required	BETHKIS *(use preferred)* inhaled tobramycin *(use preferred)*
	KITABIS	TOBI PODHALER*		
ANTICOAGULANTS	**LOW MOLECULAR WEIGHT HEPARIN (LMWH)**		Prior authorization will be required for the 300mg/3ml strength	FRAGMIN *(use preferred)* **LOVENOX 300MG/3ML***
	enoxaparin			
	DIRECT THROMBIN INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval, treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE), or for the reduction in the risk of recurrence of DVT and PE after initial therapy.	
		PRADAXA		
	SELECTIVE FACTOR XA INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation, treatment for deep vein thrombosis (DVT) prophylaxis in knee or hip replacement, treatment of DVT and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE after initial therapy.	SAVAYSA *(use preferred)*
		ELIQUIS XARELTO		
ANTICONVULSANTS	**DIAZEPAM RECTAL GEL**			diazepam gel (BRAND IS PREFERRED)
	DIASTAT*			
	ORAL ANTICONVULSANTS		Client must have a diagnosis of partial onset seizures.	
		FYCOMPA VIMPAT		
ANTIDEPRESSANTS	**ANTIDEPRESSANTS**		Trial and failure of two (2) preferred agents greater than or equal to six (6) weeks WITHIN THE LAST 2 YEARS will be required before approval can be given for a non-preferred agent. One of the trials of preferred agents must be in the same class (NaSS, NDRI, SSRI, or SNRI) as the requested non-preferred agent. Trazodone, buspirone, fluvoxamine, MAO inhibitors, TCA's, bupropion IR, and venlafaxine IR do not require prior authorization but **will not count** towards meeting preferred therapy requirements. Clients will not be allowed to be on more than one antidepressant, including fluvoxamine, bupropion IR, and venlafaxine IR, at one time with the exception of mirtazapine or bupropion with a SSRI. **Duloxetine will be approved for clients with a diagnosis of osteoarthritis of the knee or chronic low back pain. ***Brintellix requires trial and failure of two preferred agents in any class Clients five (5) years of age and younger will require prior authorization before approval. Dosage limits apply: bupropion ER/SR/XL: 450mg/day citalopram < 60 years of age: 60mg/day citalopram > 60 years of age: 30mg/day escitalopram: 30mg/day fluoxetine < 18 years of age: 90mg/day fluoxetine > 18 years of age: 120mg/day mirtazapine: 67.5mg/day paroxetine IR/CR < 18 years of age: 75mg/day paroxetine IR > 18 years of age: 90mg/day paroxetine CR > 18 years of age: 112.5mg/day sertraline: 300mg/day venlafaxine ER: 337.5mg/day	
	NORADRENERGIC/SPECIFIC SEROTONERICS (NaSS)			**NaSS**
	mirtazapine 15, 30, and 45mg			mirtazapine 7.5mg and rapid dissolve tablets *(use preferred)*
	NOREPINEPHRINE/DOPAMINE REUPTAKE INHIBITORS (NDRI)			**NDRI**
	bupropion ER/SR/XL			APLENZIN FORFIVO XL
	SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI)			**SSRI**
	citalopram escitalopram fluoxetine capsules paroxetine IR/CR sertraline			fluoxetine tablets *(use preferred)* VIIBRYD
	SEROTONIN/NORPINEPHRINE REUPTAKE INHIBITORS (SNRI)			**SNRI**
	venlafaxine ER capsules			duloxetine** desvenlafaxine FETZIMA PRISTIQ venlafaxine ER tablets *(use preferred)*
				OTHER
				BRINTELLIX***

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT GHS FOR QUESTIONS
ANTIHYPERTENSIVES	**ACE INHIBITORS**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril captopril enalapril fosinopril lisinopril moexipril perindopril quinapril ramipril trandolapril			
	ACE INHIBITORS AND DIURETICS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ moexipril/HCTZ quinapril/HCTZ			
	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	irbesartan losartan valsartan	Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.	BENICAR candesartan EDARBI eprosartan 600mg telmisartan TEVETEN 400mg
	ARBs AND DIURETICS	irbesartan HCTZ losartan HCT	Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.	BENICAR HCT candesartan HCTZ EDARBYCLOR telmisartan HCTZ TEVETEN HCTZ valsartan HCTZ
	ALPHA-BLOCKERS			clonidine patch (BRAND IS PREFERRED) NEXICLON XR *(use preferred)*
	CATAPRES PATCHES*			
	clonidine			
ANTIVIRALS	**PROTEASE INHIBITORS**			NORVIR solution *(use preferred)*
	APTIVUS CRIXIVAN INVIRASE LEXIVA NORVIR TABLETS PREZISTA REYATAZ VIRACEPT			
ANTIPSYCHOTICS	**ATYPICAL ANTIPSYCHOTICS**		**Quetiapine doses less than 100mg will require prior authorization without a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the GHS Pharmacy Help Desk for an override. Clients five (5) years of age and younger will require prior authorization before approval. Dosage limits apply: ABILIFY <13 years of age: 23mg/day ABILIFY ≥13 years of age: 45mg/day FANAPT: 36mg/day INVEGA: 18mg/day LATUDA: 240mg/day Risperidone ≤ 17 years of age: 5mg/day Risperidone > 17 years of age: 24mg/day SAPHRIS: 30mg/day Olanzapine < 13 years of age: 15mg/day Olanzapine ≥ 13 years of age: 30mg/day Quetiapine <13 years of age: 600mg/day Quetiapine 13-17 years of age: 900mg/day Quetiapine > 17 years of age: 1200mg/day ziprasidone ≤ 17 years of age: 180mg/day ziprasidone > 17 years of age: 300mg/day	ARISTADA *(use preferred)* SEROQUEL XR *(use preferred)*
	ABILIFY MAINTENA ABILIFY ODT aripiprazole FANAPT INVEGA INVEGA SUSTENNA/TRINZ LATUDA olanzapine quetiapine RISPERDAL CONSTA risperidone SAPHRIS ziprasidone ZYPREXA RELPREVV			
	SPECIAL ATYPICAL ANTIPSYCHOTICS		Dosage limits apply: 1350mg/day	VERSACLOZ Suspension (*use preferred)*
	clozapine/ODT			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
CHOLESTEROL	**BILE ACID SEQUESTRANT**		Trial and failure of ALL preferred agents greater than or equal to six (6) months in the last 12 months will be required before approval can be given for a non-preferred agent.	WELCHOL
	cholestyramine/light colestipol			
	INTESTINAL CHOLESTEROL INHIBITOR			
	ZETIA			
	NIACIN			niacin ER (BRAND IS PREFERRED)
	NIASPAN*			
	STATINS, LOW POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization.	fluvastatin/ER
	lovastatin pravastatin			
	STATINS, HIGH POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization.	CRESTOR LIVALO
	atorvastatin simvastatin			
	STATIN COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	amlodopine/atorvastatin (BRAND IS PREFERRED) CHOLESTIN LIPTRUZET PRAVIGARD
	CADUET* VYTORIN			
	TRIGLYCERIDE LOWERING AGENTS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ANTARA fenofibric fenofibrate 43, 50, 120, 130, and 150mg LIPOFEN LOVAZA VASCEPA
	fenofibrate 48, 54, 67, 134, 145, 160, and 200mg gemfibrozil			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
CONTRACEPTIVES	**ORAL CONTRACEPTIVES**			amethia/LO (BRAND IS PREFERRED) alyacen (BRAND IS PREFERRED) aranelle (BRAND IS PREFERRED) BEYAZ *(PA required)* camila *(use preferred)* camrese/LO (BRAND IS PREFERRED) cyclafem (BRAND IS PREFERRED) dasetta (BRAND IS PREFERRED) daysee (BRAND IS PREFERRED) deblitane *(use preferred)* drospir/ethi *(use preferred)* GENERESS FE CHW *(PA required)* heather *(use preferred)* introvale *(use preferred)* jencycla *(use preferred)* levonorgest/ethinyl estrad (91-Day) *(use preferred)* levonorgest/ethinyl estradiol (Continuous) 90-20 *(use preferred)* leena (BRAND IS PREFERRED) loestrin 21, FE 1/20, FE 1.5/30 *(use preferred)* LO LOESTRIN *(PA required)* LO MINASTRIN FE *(PA required)* loryna *(use preferred)* MINASTRIN 24 FE CHEWABLE *(PA required)* MODICON *(use preferred)* NATAZIA *(PA required)* necon 0.5/35, 1/35, 7/7/7 (BRAND IS PREFERRED) NECON 1/50 *(use preferred)* nikki *(use preferred)* norethindrone *(use preferred)* NORINYL 1/35 *(use preferred)* norlyroc *(use preferred)* nor-qd *(use preferred)* nortrel (BRAND IS PREFERRED) ortho micron *(use preferred)* pirmella (BRAND IS PREFERRED) quasense *(use preferred)* QUARTETTE *(PA required)* SAFYRAL *(PA required)* sharobel *(use preferred)* wera (BRAND IS PREFERRED) wymzya FE chewable (BRAND IS PREFERRED) zenchent FE chewable *(PA required)* zeosa chewable (BRAND IS PREFERRED)
	altavera amethyst azurette apri aubra aviane balzia **BREVICON*** briellyn caziant chateal cryselle delyla DESOGEN deso/ethinyl estradiol elinest emoquette enpresse enskyce errin estarylla falmina Femcon FE Chewable gianvi gildagia gildess/FE jolessa jolivette junel/FE kariva kelnor kurvelo larin/FE lessina levonest levonor/ethi levora LOESTRIN 24 FE LOMEDIA 24 FE LOSEASONIQUE low-ogestrel lutera lyza marlissa microgestin/FE mono-linyah mononessa myzilra NECON 10/11-28 nora-be norgest/ethinyl estradiol noreth/ethin FE 1/20 NORINYL 1/50-28 ocella OGESTREL orsythia ORTHO-CEPT **ORTHO TRI-CYCLEN LO*** **ORTHO-NOVUM 1/35-28, 7/7/7-28*** philith pimtrea portia previfem reclipsen **SEASONIQUE*** sprintec sronyx syeda tilia FE tri-estaryll tri-legest FE tri-linyah trinessa **TRI-NORINYL*** tri-previfem tri-sprintec trivora velivet vestura viorele vyfemla zarah zenchent ZOVIA			
CORTICOSTEROIDS	**ORAL CORTICOSTEROIDS**			CELESTONE *(use preferred)*
	budesonide cortisone acetate dexamethasone/intensol hydrocortisone methylprednisone prednisolone prednisone			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
DIABETES	**DIABETES AGENTS**			FORTAMET *(use preferred)* GLUMETZA *(use preferred)* RIOMET *(use preferred)*
	BIGUANIDES			
	metformin/ER			
	α–GLUCOSIDASE INHIBITORS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	GLYSET
	acarbose			
	MEGLITINIDES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	nateglinide (BRAND IS PREFERRED) repaglinide
	STARLIX*			
	THIAZOLIDINEDIONES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACTOSPLUS MET *(use separate agents)* AVANDIA AVANDAMET *(use separate agents)*
	pioglitazone			
	SULFONYLUREAS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	glimepiride/ER glipizide/ER glyburide/ER			
	DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	GLYXAMBI *(use separate preferred agents)* NESINA TRADJENTA
		JANUVIA ONGLYZA		
	DPP-4 INHIBITOR COMBO AGENTS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	JENTADUETO JUVISYNC KAZANO OSENI
		JANUMET/XR KOMBIGLYZE		
	INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	BYETTA TANZEUM TRULICITY
		BYDUREON VICTOZA		
	SGLT2 INHIBITORS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	GLYXAMBI *(use separate preferred agents)* INVOKANA JARDIANCE
		FARXIGA		
	SGLT2 INHIBITOR COMBO AGENTS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	INVOKAMET SYNJARDY
		XIGDUO XR		
	LONG-ACTING INSULIN		Prior authorization will be required when using two different delivery forms of the same type of insulin concurrently	LANTUS OPTICLIK *(use preferred)* TOUJEO *(use preferred)*
	LANTUS SOLOSTAR LANTUS vial LEVEMIR			
	DIABETIC METERS/TEST STRIPS		Quantity limits apply: Insulin Dependent Clients: 10 strips/day Non-Insulin Dependent Clients: 4 strips/day Clients are limited to 1 meter/365 days	ALL OTHER METERS AND TEST STRIPS
	FREESTYLE INSULINX FREESTYLE LITE FREESTYLE FREEDOM LITE ONE TOUCH ULTRA ONE TOUCH ULTRA 2 ONE TOUCH ULTRA MINI ONE TOUCH ULTRASMART ONE TOUCH VERIO PRECISION XTRA			
EAR	**ANTIBIOTIC/STEROID COMBINATION**			ciprofloxacin 0.2% *(use preferred)* CIPRO HC *(use preferred)* COLY-MYCIN S *(use preferred)* CORTISPORIN-TC *(use preferred)* FLUOCINOLONE ACET OIL 0.01% *(use preferred)* ofloxacin *(use preferred)*
	CIPRODEX Neo/Poly/HC Suspension and Solution			
FIBROMYALGIA	**FIBROMYALGIA STEP 1**			
	amitriptyline cyclobenzaprine			
	FIBROMYALGIA STEP 2		Trial and failure of a Step 1 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 2 agent.	
		SAVELLA		
	FIBROMYALGIA STEP 3		Trial and failure of a Step 1 agent and a Step 2 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 3 agent.	
		duloxetine LYRICA		
GASTROINTESTINAL	**BOWEL PREP**			
	PREPOPIK			
	DIGESTIVE ENZYMES		Prior authorization required.	PANCREAZE PERTZYE TRI-PASE ULTRESA VIOKASE
	CREON 3000, 6000, 12000, 24000, and 36000 units pancrelipase ZENPEP			
	IRRITABLE BOWEL SYNDROME AGENTS		Client must have a diagnosis of chronic idiopathic constipation or Irritable Bowel Syndrome (IBS) with constipation.	
		AMITIZA LINZESS		

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
GASTROINTESTINAL continued	**OPIOID-INDUCED CONSTIPATION AGENTS**	AMITIZA	Client must have a diagnosis of opioid-induced constipation and a three (3) month trial and failure of a secretory agent to receive the preferred agent. To receive the non-preferred agent, client must have a diagnosis of opioid-induced constipation, a three (3) month trial and failure of a secretory agent, and a three (3) month trial and failure of the preferred agent.	MOVANTIK
	PROTON PUMP INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Lansoprazole solutabs will be approved for children less than or equal to 8 years of age.	ACIPHEX SPRINKLES amox/clarith/lanso pack *(use separate agents)* DEXILANT esomeprazole 24.65mg and 49.3mg lansoprazole solutabs **NEXIUM*** omeprazole 20.6mg capsules *(use preferred)* omeprazole tablets *(use preferred)* omeprazole/sodium bicarbonate OMECLAMOX *(use separate agents)* rabeprazole VIMOVO *(use separate agents)*
	lansoprazole capsules omeprazole capsules pantoprazole			
	MESALAMINE		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	APRISO ASACOL/HD CANASA LIALDA PENTASA 500MG (use preferred) ROWASA
	DELZICOL mesalamine enema PENTASA 250MG ONLY			
GROWTH HORMONE	**GROWTH HORMONE**	GENOTROPIN NORDITROPIN NUTROPIN AQ	PA is required for use outside of FDA-approved indications. Evaluation by an endocrinologist is preferred. Clinical evidence of improved growth will be required on a yearly basis to support ongoing utilization. Clinical evidence of need for growth hormone will be required for adult growth hormone deficiency and pediatric growth failure due to inadequate endogenous growth hormone. Trial and failure of two (2) preferred agents within the last 12 months will be required for the following indications: Pediatric: Growth failure due to inadequate endogenous growth hormone, Prader-Willi syndrome, children born small for gestation. Turner syndrome. Adult: Replacement for those with growth hormone deficiency.	HUMATROPE OMNITROPE SAIZEN SEROSTIM TEV-TROPIN ZORBTIVE
HEART FAILURE	**NEPRILYSIN INHIBITOR AND ARB COMBO**			
	ENTRESTO			
HEPATITIS C	**NSSA INHIBITOR**	DAKLINZA	Limited to FDA approved indication. Prior authorization will be required prior to use of Daklinza. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
	NUCLEOTIDE ANALOG POLYMERASE INHIBITOR	SOVALDI	Limited to FDA approved indication. Prior authorization will be required prior to use of Sovaldi. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
	PROTEASE INHIBITOR	OLYSIO	Limited to FDA approved indication. Prior authorization will be required prior to use of Olysio. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
	HEP C COMBO AGENTS	HARVONI TECHNIVIE VIEKIRA PAK	Limited to FDA approved indication. Prior authorization will be required prior to use of Harvoni, Technivie, or Viekira Pak. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org.	
IMMUNOMODULATORS	**ANKYLOSING SPONDYLITIS (AS)**	ENBREL HUMIRA	Client must have diagnosis of AS prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of AS and a 56-day trial and failure of both preferred agents. Quantity Limits apply for all diagnoses: Enbrel 25mg - limited to 10 per month Enbrel 50mg - limited to 5 per month Humira 20mg - limited to 10 per month Humira 40mg - limited to 5 per month	CIMZIA REMICADE SIMPONI
	CROHN'S	HUMIRA	Client must have diagnosis of Crohn's prior to approval of the preferred agent. To receive a non-preferred agent, client must have a diagnosis of Crohn's and a 56-day trial and failure of the preferred agent.	CIMZIA REMICADE TYSABRI *(additional criteria applies)*
	HIDRODENITIS SUPPURATIVA		Humira will not be covered as a first line agent for the diagnosis for hidrodenitis suppurativa.	
	HUMIRA			
	JUVENILE IDIOPATHIC ARTHRITIS (JIA)	ENBREL HUMIRA	Client must have diagnosis of JIA prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of JIA and a 56-day trial and failure of both preferred agents.	ORENCIA
	PSORIATIC ARTHRITIS (PA)	ENBREL HUMIRA	Client must have diagnosis of PA prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of PA and a 56-day trial and failure of both preferred agents.	CIMZIA OTEZLA REMICADE SIMPONI

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT DHS FOR QUESTIONS)
IMMUNOMODULATORS continued	**PLAQUE PSORIASIS (PP)**		Client must have diagnosis of PP prior to approval of a step 1 agent (Enbrel or Humira). To receive the step 2 agent (Cosentyx), client must have a diagnosis of PP and a 56-day trial and failure of Humira. To receive a non-preferred agent, client must have a diagnosis of PP and a 56-day trial and failure of both preferred agents.	OTEZLA REMICADE STELARA
	STEP 1 AGENTS			
		ENBREL HUMIRA		
	STEP 2 AGENT			
		COSENTYX**		
	RHEUMATOID ARTHRITIS (RA)		Client must have diagnosis of RA and a 56-day trial and failure of methotrexate prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of RA and a 56-day trial and failure of both preferred agents.	ACTEMRA CIMZIA KINERET ORENCIA REMICADE RITUXAN SIMPONI XELJANZ
		ENBREL HUMIRA		
	ULCERATIVE COLITIS (UC)		Client must have diagnosis of UC prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of UC and a 56-day trial and failure of the preferred agent.	REMICADE
		HUMIRA		
INSOMNIA	**NON-BENZODIAZEPINES**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 18. Rozerem is non-preferred without a history of substance abuse Prior authorization will be required when a client is taking more than one insomnia agent concurrently. Dosage limits apply: zaleplon: 30mg/day zolpidem: 15mg/day	BELSOMRA EDLUAR *(additional criteria applies)* eszopiclone INTERMEZZO *(additional criteria applies)* ROZEREM zolpidem ER ZOLPIMIST *(additional criteria applies)*
	zaleplon zolpidem			
MIGRAINE	**TRIPTANS**		Trial and failure of all preferred agents will be required for approval of a non-preferred agent. Rizatriptan will be approved for clients between 6 and 17 years of age Quantity limits apply: naratriptan 1mg: 25 tabs/34 days naratriptan 2.5mg: 10 tabs/34 days sumatriptan vials: 2 vials/34 days sumatriptan nasal: 6 bottles/34 days sumatriptan 25mg: 41 tabs/34 days sumatriptan 50mg: 20 tabs/34 days sumatriptan 100mg: 10 tabs/34 days	almotriptan FROVA RELPAX rizatriptan TREXIMET ZECUITY PAD *(use preferreds)* zolmitriptan
	naratriptan sumatriptan			
MULTIPLE SCLEROSIS	**STEP 1 MS AGENTS**		Trial and failure of one preferred agent will be required before approval can be given for the step 2 MS agent (Gilenya). Trial and failure of a preferred step 1 interferon agent AND trial and failure of Copaxone 20mg/ml will be required before approval can be given for a non-preferred agent. For Tysabri, in addition to the above criteria, additional prior authorization criteria applies.	COPAXONE 40MG/ML *(use preferred)* EXTAVIA LEMTRADA PLEGRIDY TECFIDERA TYSABRI (additional criteria applies)
	IMMUNOMODULATOR (GLATIRAMER INJECTION)			
	COPAXONE 20MG/ML			
	INTERFERON			
	AUBAGIO AVONEX BETASERON REBIF			
	STEP 2 MS AGENTS			
		GILENYA		
NEUROPATHIC PAIN	**TRICYCLIC ANTIDEPRESSANTS**		For the diagnosis of neuropathic pain, trial and failure of a tricyclic antidepressant greater than or equal to a 12 week supply AND trial and failure of gabapentin at a dose of 3600mg per day for greater than or equal to a 12 week supply in the last 12 months will be required before approval can be given for a non-preferred agent.	duloxetine LYRICA
		amitriptyline desipramine imipramine nortriptyline		
	GABAPENTIN			
		gabapentin		
NSAIDS	**NSAIDs**		Trial and failure of two (2) preferred agents each greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosing and quantity limits apply for ketorolac (limit 5days/34 days; max dose 40mg/day for oral tablets).	CALDOLOR *(use preferred)* CAMBIA POWDER *(use preferred)* celecoxib diclofenac 1.5% solution *(additional criteria applies)* diclofenac 3% gel *(additional criteria applies)* fenoprofen FLECTOR *(additional criteria applies)* mefenamic acid NEOPROFEN *(use preferred)* SPRIX *(additional criteria applies)* TIVORBEX *(use preferred)* VOLTAREN *(additional criteria applies)* ZIPSOR *(use preferred)* ZORVOLEX *(use preferred)*
	diclofenac *tablets* etodolac flurbiprofen ibuprofen indomethacin ketoprofen ketorolac meclofenamate meloxicam nabumetone naproxen oxaprozin piroxicam sulindac tolmetin			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT DHS FOR QUESTIONS)
OPHTHALMICS	**OP. -ANTI-ALLERGICS**		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Emadine, Alomide, and Alocril will be approved for pregnancy. Alomide will be approved for children under the age of 3.	ALAMAST ALOCRIL ALOMIDE ALREX azelastine BEPREVE EMADINE epinastine ketotifen LASTACAFT PAZEO
	cromolyn PATADAY PATANOL			
	OP. -ANTIBIOTICS- QUINOLONES		Trial and failure of a preferred agent greater than or equal to 5 days in the last 12 months will be required before approval can be given for a non-preferred agent. Azasite will be approved for pregnancy.	AZASITE BESIVANCE gatifloxacin IQUIX levofloxacin ZYMAR
	ciprofloxacin ofloxacin MOXEZA VIGAMOX			
	OP. -ANTI-INFLAMMATORY- NSAIDS		Trial and failure of ALL preferred agents each greater than or equal to 5 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACULAR/LS/PF *(use preferred)* ACUVAIL bromfenac 0.9% PROLENSA
	flurbiprofen diclofenac ketorolac ILEVRO NEVANAC			
	OP. -BETA-BLOCKERS		Trial and failure of three (3) preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Betoptic S will be approved for those with heart and lung conditions.	BETIMOL BETOPTIC S ISTALOL
	betaxolol carteolol levobunolol metipranolol timolol			
	OP. -CARBONIC ANHYDRASE INHIBITOR		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	AZOPT
	dorzolamide			
	OP. - COMBO PRODUCTS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	
	COMBIGAN dorzolamide/timolol SIMBRINZA			
	OP. -PROSTAGLANDINS		Trial and failure of ALL preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	bimatoprost LUMIGAN 0.1% ZIOPTAN
	latanoprost TRAVATAN Z			
	OP. -SYMPATHOMIMETICS		Trial of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	ALPHAGAN P 0.1% brimonidine 0.15% (BRAND IS PREFERRED)
	ALPHAGAN P 0.15%* brimonidine 0.2%			
OSTEOPOROSIS	**BISPHOSPHONATES**		Trial and failure of a preferred agent greater than or equal to 12 months will be required before approval can be given for a non-preferred agent. Fosamax liquid will be approved for clients that have difficulty swallowing.	risedronate ATELVIA FOSAMAX-D ibandronate
	alendronate			
	NASAL CALCITONIN			
	calcitonin-salmon fortical			
OVERACTIVE BLADDER	**OVERACTIVE BLADDER AGENTS**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	ENABLEX GELNIQUE GEL 10% MYRBETRIQ OXYTROL DIS SANCTURA XR tolterodine/ER trospium
	oxybutynin /ER TOVIAZ VESICARE			
PHOSPHATE BINDERS	**PHOSPHATE BINDERS**		Prior authorization required for non-preferred agents.	AURYXIA FOSRENOL RENAGEL 800MG *(use preferred)* sevelamer VELPHORO
	calcium acetate PHOSLYRA RENAGEL 400mg			
PLATELET AGGREGATE INHIBITORS	**THIENOPYRIDINE DERIVATIVES**		Prior authorization reuquired for clients on antiplatelet therapy greater than one (1) year.	
	clopidogrel EFFIENT ticlopidine			
	CPTP DERIVATIVES		Prior authorization is required.	BRILINTA
	PAR-1 ANTAGONIST	ZONTIVITY	Client must have diagnosis reduction of thrombotic cardiovascular events with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). Must be used in conjunction with aspirin or clopidogrel.	
PROGESTIN	**PROGESTIN**	MAKENA	Prior authorization is required.	
PROSTATE	**5-ALPHA-REDUCTASE INHIBITORS**		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	dutasteride JALYN *(use separate agents)*
	finasteride			
	ALPHA BLOCKERS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	alfuzosin JALYN *(use separate agents)* RAPAFLO
	doxazosin tamsulosin terazosin			
PULMONARY ANTIHYPERTENSIVES	**5-ALPHA-REDUCTASE INHIBITORS**	ADCIRCA REVATIO SUSPENSION sildenafil (Revatio A/B rated generic)	Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
	ENDOTHELIN RECEPTOR ANTAGONISTS	LETAIRIS TRACLEER	Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	OPSUMIT
	PROSTACYCLINE VASODILATOR	ORENITRAM	Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
RESTLESS LEG SYNDROME	**RESTLESS LEG SYNDROME**	gabapentin pramipexole ropinirole	Client must have a diagnosis of Restless Leg Syndrome (RLS). Trial and failure of gabapentin greater than or equal to 60 days and a trial and failure of a dopamine agonist greater than or equal to 60 days in the last 12 months will be required before approval can be given for a non-preferred agent. *Neupro will be approved for clients with difficulty swallowing or for clients with a diagnosis of Parkinson's Disease.	HORIZANT NEUPRO*
SKELETAL MUSCLE RELAXANTS	**MUSCLE RELAXANTS** baclofen cyclobenzaprine tizanidine tablets		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months, along with a medical diagnosis of muscle spasticity will be required before approval can be given for a non-preferred agent. Cyclobenzaprine will require a prior authorization for clients concurrently taking a tricylic antidepressant.	carisoprodol chlorzoxazone cyclobenzaprine ER metaxalone methocarbamol orphenadrine tizanidine capsules *(use preferred)* Carisoprodol is limited to 84 tabs/365 days
STIMULANT	**AMPHETAMINES** **LONG ACTING AMPHETAMINES**	**ADDERALL XR*** **DEXEDRINE CAPSULES*** VYVANSE**	Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, MS fatigue (see MS Fatigue criteria below), or refractory depression (see refractory depression criteria below). Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue. Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 4. **Vyvanse will be approved for the diagnosis of binge-eating disorder for clients 18 years of age and older. Authorizations will be approved for 12 weeks, and further use of Vyvanse for this diagnosis will require additional documentation prior to approval. ***Only authorized generics for Concerta will be covered. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Trial and failure of two (2) preferred agents (each from a different class: methylphenidate and amphetamine) greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosage limits apply: amphetamine salts combo XR: 60mg/day amphetamine salts combo: 60mg/day amphetamine salts combo (narcolepsy): 90mg/day DAYTRANA: 45mg/9 hour patch/day dextroamphetamine: 90mg/day dextroamphetamine CR: 90mg/day dexmethylphenidate: 30mg/day FOCALIN XR < 13 years of age: 45mg/day FOCALIN XR > 13 years of age: 60mg/day methylin/methylphenidate/ER: 90mg/day VYVANSE: 105mg/day	**AMPHETAMINES:** amphetamine salts combo XR (BRAND IS PREFERRED) dextroamphetamine CR capsules (BRAND IS PREFERRED) ZENZEDI 2.5 AND 7.5MG TABLETS
	IMMEDIATE RELEASE AMPHETAMINES	amphetamine salts combo* dextroamphetamine tablets		
	METHYLPHENIDATES **LONG ACTING METHYLPHENIDATES**	DAYTRANA **FOCALIN XR*** methylin ER methylphenidate ER/CR/SA/SR tablets***		**METHYLPHENIDATES:** APTENSIO XR dexmethylphenidate ER (BRAND IS PREFERRED) methylphenidate ER/CR/SR capsules (METADATE CD/RITALIN LA) QUILLIVANT XR SUSPENSION
	IMMEDIATE RELEASE METHYLPHENIDATES	dexmethylphenidate methylin tablets		

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
STIMULANT-LIKE AGENTS	**SELECTIVE ALPHA-ADRENERGIC AGONIST**		To obtain the **non-preferred agent**, client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. To receive Kapvay, clients must have completed a 14 day trial of clonidine IR with benefit in the previous 12 months.	**KAPVAY***
	clonidine			
	GUANFACINE AGENTS		To obtain the **non-preferred agent**, client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. To receive Intuniv, clients must have a trial and failure of a stimulant greater than or equal to a 14 day supply OR a trial and failure of Strattera greater than or equal to a 30 day supply **AND** a 14 day trial of guanfacine with benefit in the previous 12 months, OR a contraindication to ADHD medications (including stimulant and non-stimulant), OR a TIC disorder associated with stimulants (trial of stimulant required).	**INTUNIV***
	guanfacine			
STIMULANT-LIKE AGENTS cont.	**SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR**	STRATTERA	Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, or refractory depression (see refractory depression criteria below). Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 4. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Dosage limits apply: STRATTERA: 150mg/day	

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at *http://wymedicaid.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT DHS FOR QUESTIONS
TOPICAL AGENTS	**IMPETIGO ANTIBIOTICS**		Trial and failure of ALL preferred agents greater than or equal to 7 days in the past 90 days. Use smallest size appropriate for 7 day trial.	ALTABAX
	gentamicin mupirocin			
	BENZOYL PEROXIDE/CLINDAMYCIN COMBOs		Clients must be 12 to 20 years of age and have a diagnosis of acne vulgaris. Requires prior authorization for clients less than 12 years of age. Acne combinations are limited to clients under the age of 21.	ACANYA benzoyl peroxide/clindamycin (BRAND IS PREFERRED)
		BENZACLIN*		
		clindamycyin/benzoyl peroxide 1.2 (1)-5% (Refrig)		
	CORTICOSTEROIS		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	PANDEL prednicarbate 0.1% (C,O) TEXACORT 2.5% (S)
	LOW POTENCY			
	alclometasone desonide DESOWEN 0.05% (L) fluocinolone 0.01% hydrocortisone butyrate 0.1% (C) hydrocortisone 1%, 2.5% (C,L,O) SYNALAR 0.01%			
	MEDIUM POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	Clocortolone Pivalate CORDRAN/SP fluticasone 0.05% (L) hydrocortisone butyrate 0.1% (O) TOPICORT LP TRIANEX
	betamethasone valerate CUTIVATE 0.05% (C) DERMATOP 0.1% (C) desoximetasone 0.05% (C) ELOCON 0.1% fluocinolone 0.025% fluticasone 0.05% (C) hydrocortisone probutate 0.1% (C) mometasone SYNALAR 0.025% TOPICORT 0.05% (C) triamcinolone 0.025%, 0.1%			
	HIGH POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	APEXICON amcinonide 0.1% (C,L,O) augmented betamethasone 0.05% (G,L,O) clobetasol 0.05% (L) desoximetasone 0.05%, 0.25% (C,G,O) fluocinonide 0.1% (C) HALOG
	betamethasone dipropionate clobetasol/E 0.05% (C,G,O,S) diflorasone DIPROLENE 0.05% (L) fluocinonide flurandrenolide fluticasone 0.005% (O) halobetasol TEMOVATE/E TOPICORT 0.25% (C) triamcinolone 0.5% ULTRAVATE 0.05%			
	IMMUNOMODULATORS		Trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial and a trial and failure of a preferred high potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days. For clients less than two (2) years of age, a trial and failure of a preferred low potency corticosteroid greater than or equal to a 21 day trial and a trial and failure of a preferred medium potency topical cortiscosteroid greater than or equal to a 21 day trial in the last 90 days.	
		ELIDEL PROTOPIC		
	SALICYLIC ACID			All other topical salicylic acid formulations.
	salicylic acid cream 6% salicylic acid lotion 6% salicylic acid shampoo 6%			
	SCABICIDES/PEDICULICIDES		Trial and failure of a preferred agent in the last 12 months.	LINDANE OVIDE permethrin cream ULESFIA
	NATROBA permethrin solution SKLICE			
	UREA			All other topical urea formulations.
	ALUVEA CREAM 33% UMECTA EMULSION umecta mousse aerosal 40% urea lotion 40% urea lotion 45%			